文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

氢化可的松治疗重症社区获得性肺炎的Meta分析

[Meta-analysis of hydrocortisone in the treatment of severe community-acquired pneumonia].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论Meta分析显示氢化可的松可降低重症社区获得性肺炎患者死亡率(6.0% vs 14.0%,OR=0.38),且不增加高血糖、消化道出血或继发感染风险。

该Meta分析纳入5项RCT共1031例重症社区获得性肺炎患者(标准治疗组494例,氢化可的松组537例),比较氢化可的松联合标准治疗与单纯标准治疗的疗效与安全性。结果显示氢化可的松组死亡率显著低于标准治疗组(6.0% vs 14.0%,OR=0.38,95%CI 0.25-0.59,P<0.01),8天机械通气率显著降低(19.5% vs 55.4%,OR=0.24),机械通气时间无统计学差异。高血糖、消化道出血、继发感染发生率两组无显著差异。试验序贯分析提示实际样本量超过所需样本量,氢化可的松可有效降低死亡率。

要点

  • 氢化可的松组死亡率6.0% vs 标准治疗组14.0%,OR=0.38(95%CI 0.25-0.59,P<0.01),I²=9%。
  • 氢化可的松组8天机械通气率19.5% vs 标准治疗组55.4%,OR=0.24(95%CI 0.12-0.45,P<0.01),I²=0%。
  • 机械通气时间两组无统计学差异(MD=-3.26,95%CI -6.72-0.21,P=0.07),I²=0%。
  • 高血糖(OR=1.26,95%CI 0.56-2.84)、消化道出血(OR=0.70,95%CI 0.34-1.46)、继发感染(OR=0.46,95%CI 0.06-3.35)发生率两组无显著差异。
  • 试验序贯分析:标准治疗组平均死亡率约14.0%,氢化可的松组约6.0%,相对风险降低57%,所需样本量699例,实际样本量1031例超过所需,Z曲线跨过O'Brien-Fleming界值和P=0.05对应曲线。

适用人群与场景

  • 重症社区获得性肺炎(sCAP)患者,来自5项RCT共1031例(标准治疗组494例,氢化可的松组537例)。
  • 5项研究中2项研究的研究场所为混合病房,考虑到研究人群的纳入特征,其研究对象是否为sCAP患者存在疑问,可能对结果有一定影响并引入潜在偏倚。

处置流程与药物剂量

  • 标准治疗组接受抗生素和支持治疗等标准治疗;氢化可的松组在标准治疗基础上接受氢化可的松治疗。

研究设计与关键结果

  • 研究类型:Meta分析,纳入5项RCT,共1031例患者(标准治疗组494例,氢化可的松组537例),检索截至2023年4月29日。
  • 主要终点死亡率:氢化可的松组6.0% vs 标准治疗组14.0%,OR=0.38(95%CI 0.25-0.59,P<0.01),I²=9%;减补法校正后OR=0.49(95%CI 0.32-0.73,P<0.01),I²=31%。
  • 机械通气时间:氢化可的松组 vs 标准治疗组 MD=-3.26(95%CI -6.72-0.21,P=0.07),I²=0%,无统计学差异。
  • 8天机械通气率:氢化可的松组19.5% vs 标准治疗组55.4%,OR=0.24(95%CI 0.12-0.45,P<0.01),I²=0%。
  • 高血糖:氢化可的松组54.3% vs 标准治疗组44.6%,OR=1.26(95%CI 0.56-2.84,P=0.58),I²=61%,无显著差异。
  • 消化道出血:氢化可的松组2.5% vs 标准治疗组3.6%,OR=0.70(95%CI 0.34-1.46,P=0.34),I²=0%,无显著差异。
  • 继发感染:氢化可的松组9.2% vs 标准治疗组11.5%,OR=0.46(95%CI 0.06-3.35,P=0.45),I²=53%,无显著差异。
  • 试验序贯分析:标准治疗组平均死亡率约14.0%,氢化可的松组约6.0%,RRR=57%,计算样本量699例,实际样本量1031例超过所需,Z曲线跨过O'Brien-Fleming界值和P=0.05对应曲线,表明氢化可的松可有效降低sCAP死亡率。

证据类型、等级与局限

  • 证据类型:Meta分析(纳入5项RCT)。
  • 5项研究中2项研究的研究场所为混合病房,其研究对象是否为sCAP患者存在疑问,可能对结果有一定影响并引入潜在偏倚。
  • 采用减补法对可能存在发表偏倚的研究进行校正,校正后氢化可的松仍可降低死亡风险(OR=0.49,95%CI 0.32-0.73,P<0.01)。
  • 局限:原文未报告其他局限性。

对床旁实践的改变

  • 作者认为氢化可的松可降低sCAP患者死亡率、减少机械通气需求,且不增加高血糖、消化道出血或继发感染风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore whether hydrocortisone can improve the prognosis of patients with severe community-acquired pneumonia (sCAP) by Meta-analysis.

METHODS: Randomized controlled trial (RCT) on hydrocortisone in the treatment of sCAP were extracted from the database including PubMed, Cochrane library, Web of Science, and Embase, and the search time was up to April 29, 2023. The patients in the standard treatment group received standard treatment such as antibiotics and supportive care, while those in the hydrocortisone group received hydrocortisone treatment on the basis of standard treatment. Meta-analysis was used to compare the mortality, duration of mechanical ventilation, mechanical ventilation rate and incidence of adverse reactions (hyperglycemia, gastrointestinal bleeding, secondary infection) between the two groups. The risk of literature bias was assessed. The studies that might have publication bias were corrected by the subtraction and complementation method. At the same time, trial sequential analysis (TSA) was conducted.

RESULTS: A total of 5 RCTs involving 1 031 patients were finally enrolled, including 494 patients in the standard treatment group and 537 patients in the hydrocortisone group. Among the 5 studies, the research site of 2 studies was in the mixed ward. Considering the inclusion characteristics of the study population, there was doubt whether its research object was sCAP patients, which might have a certain impact on the results and introduce potential bias. Meta-analysis showed that the mortality in the hydrocortisone group was significantly lower than that in the standard treatment group [6.0% vs. 14.0%; odds ratio (OR) = 0.38, 95% confidence interval (95%CI) was 0.25-0.59, P < 0.01; I2 = 9%]. The studies that were asymmetric were corrected by the reduction and supplementation method. Even after filling the missing studies, hydrocortisone could still reduce the death risk of the patient (OR = 0.49, 95%CI was 0.32-0.73, P < 0.01; I2 = 31%). TSA showed that the average mortality of the standard treatment group was about 14.0%, and that of the hydrocortisone group was about 6.0%, with a relative risk reduction (RRR) = 57%. The calculated sample size was 699 cases, and the actual sample size was 1 031 cases. The actual sample size exceeded the required sample size, and the Z-curve crossed the O'Brien-Fleming boundary and the curve corresponding to P = 0.05, it meant that hydrocortisone could effectively reduce the mortality of sCAP. Compared with the standard treatment group, no statistical difference in the duration of mechanical ventilation was found in the hydrocortisone group [mean difference (MD) = -3.26, 95%CI was -6.72-0.21, P = 0.07; I2 = 0%], but the 8-day mechanical ventilation rate was significantly lowered (19.5% vs. 55.4%; OR = 0.24, 95%CI was 0.12-0.45, P < 0.01; I2 = 0%), and also no significantly difference was found in the incidence of hyperglycemia (54.3% vs. 44.6%, OR = 1.26, 95%CI was 0.56-2.84, P = 0.58; I2 = 61%), gastrointestinal bleeding (2.5% vs. 3.6%; OR = 0.70, 95%CI was 0.34-1.46, P = 0.34; I2 = 0%) and secondary infection (9.2% vs. 11.5%; OR = 0.46, 95%CI was 0.06-3.35, P = 0.45; I2 = 53%).

CONCLUSION: Hydrocortisone can reduce the mortality rate of sCAP patients, decrease their need for mechanical ventilation, and does not increase the risk of hyperglycemia, gastrointestinal bleeding, or secondary infections.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Gu X, Yang P, Yu L, et al. [Meta-analysis of hydrocortisone in the treatment of severe community-acquired pneumonia]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40820529. doi:10.3760/cma.j.cn121430-20230710-00500

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。